25.09.2021 18:15

New Study Highlights the Value of Genetic Testing to Guide Clinical Management and Improve Outcomes for Epilepsy Patients

Folgen
Werbung

SAN FRANCISCO, Sept. 25, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today presented research demonstrating that genetic findings informed clinical management changes that led to improved seizure control and outcomes in the majority of epilepsy patients with actionable findings. This study underscores the importance of genetic testing for all people with epilepsy and supports the growing evidence that medical genetic testing can improve health outcomes and reduce healthcare costs. The findings were presented at the National Society of Genetic Counselors 40th Annual Conference.

Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people.  www.invitae.com (PRNewsFoto/Invitae Corporation)

"Epilepsy impacts the lives of approximately 50 million people worldwide and our findings further demonstrate the value of genetic testing to drive precision treatment decisions for these patients," said lead study author, Dee McKnight, PhD, FACMG. "These results build on the growing evidence that genetic testing at the first presentation with epilepsy can be a key part of an accurate diagnosis and can play an important role in its initial treatment and ongoing management, improving health outcomes and reducing healthcare costs."

Notably, the research found that a change in clinical management once genetic results were received was reported by clinicians for nearly half of patients. Furthermore, the majority of cases had a change in clinical management within three months of receiving positive genetic testing results, such as antiseizure medication adjustments. Positive patient outcomes were reported in 75 percent of patients, including reduction or complete resolution of seizures after treatment changes as well as improvements in behavior, development, academics and movement issues.

The research was virtually presented at the annual meeting of the National Society of Genetic Counselors. The full research presentation from Invitae included:

Oral platform presentations:

  • Epilepsy genetic testing guides clinical management and helps improve patient outcomes. Presented by Ana Morales, MS, CGC (Invitae)
  • Underutilization of germline testing for prostate cancer patients: Are genetic testing criteria a tool or an obstacle? Presented by Sarah Nielsen, MS, CGC (Invitae)
  • Genetics professionals' perspectives on the reporting of variants of uncertain significance (VUS) - Should they always be returned? Presented by Michelle Fox, MS, LCGC (Invitae)
  • Poster presentations:
  • PTC Pinpoint CP Spectrum: A sponsored, no-cost 265-gene panel for patients with symptoms suggestive of CP and absence of risk factors for an acquired brain injury. Presented by Jeffrey Kopesky (PTC Therapeutics)
  • Improving the rate of positive results in reproductive carrier screening by leveraging variant classification evidence derived from diagnostic genetic testing in affected individuals. Presented by Julia Wilkinson, MS, CGC (Invitae)

In addition to presenting its research, Invitae partnered with NSGC to present the Heart of Genetic Counseling Award, which honors excellence in genetic counseling and patient care as recognized by patients. Nominations included stories from patients that highlight both the clinical and personal impact a genetic counselor had on their lives and the lives of their families.

The 2021 Heart of Genetic Counseling Award winner was Pilar Magoulas, MS, CGC of Baylor College of Medicine/Texas Children's Hospital. Nominated for her devotion to families with cardiofaciocutaneous (CFC) syndrome and years of volunteering that has helped expand the understanding of CFC syndrome and helped hundreds of families better care for their loved ones with syndrome-specific information.

Other finalists included Amie Hass, MSN, ARNP, Hall-Perrine Cancer Center, Cedar Rapids, IA, for her work helping a family with Li-Fraumeni syndrome, a genetic condition that increases cancer risk, by outlining the necessary preventative care and finding the best treatment protocol when cancers occurred. Prescilla Carrion, MSc, CGC, CCGC, Department of Psychiatry, University of British Columbia, was also named a finalist for using the family tree as a tool to help people with mental health issues understand the role of genetics.

About Invitae

Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the findings and implications of the study; and the value of genetic testing to guide clinical management and improve outcomes for epilepsy patients. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to:  the company's history of losses; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in Invitae's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. These forward-looking statements speak only as of the date hereof, and Invitae disclaims any obligation to update these forward-looking statements.

Contact:
pr@invitae.com
(628) 213-3283

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/new-study-highlights-the-value-of-genetic-testing-to-guide-clinical-management-and-improve-outcomes-for-epilepsy-patients-301385074.html

SOURCE Invitae Corporation

Nachrichten zu Invitae Corp

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Invitae Corp

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
07.08.2019Invitae BuyThe Benchmark Company
04.03.2019Invitae BuyChardan Capital Markets
19.12.2018Invitae OutperformOppenheimer & Co. Inc.
20.11.2018Invitae BuyThe Benchmark Company
13.02.2018Invitae BuyThe Benchmark Company
07.08.2019Invitae BuyThe Benchmark Company
04.03.2019Invitae BuyChardan Capital Markets
19.12.2018Invitae OutperformOppenheimer & Co. Inc.
20.11.2018Invitae BuyThe Benchmark Company
13.02.2018Invitae BuyThe Benchmark Company
30.06.2016Invitae HoldThe Benchmark Company
14.08.2015Invitae Mkt PerformWilliam Blair

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Invitae Corp nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Werbung

Meistgelesene Invitae News

Keine Nachrichten gefunden.
Weitere Invitae News
Werbung
Werbung
Werbung
Börse Stuttgart Anlegerclub
Werbung

Invitae Peer Group News

Keine Nachrichten gefunden.

Heute im Fokus

Dow schließt im Plus -- DAX geht fester in den Feierabend -- Hertz bestellt 100.000 Teslas -- ifo-Index sinkt -- Finanzinvestoren wollen zooplus gemeinsam übernehmen -- BASF, Deutsche Bank im Fokus

Wachstum von Michelin schwächt sich ab. Moderna: Corona-Impfung bei Kindern mit 'robuster Wirkung'. Microsoft warnt vor weiteren Hackerangriffen. Daimler Truck erhält Straßenzulassung für Brennstoffzellen-Lkw. PayPal: Verfolgen derzeit nicht den Kauf von Pinterest. FUCHS PETROLUB-Aufsichtsratschef Bock gibt 2022 sein Amt auf. Italien blockiert offenbar Verisem-Übernahme durch Syngenta.

Umfrage

Würden Sie eine verpflichtende Corona-Impfung gutheißen?

finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln